Researching Sanfilippo syndrome скачать в хорошем качестве

Researching Sanfilippo syndrome

In this weeks Dementia Researcher Podcast, we hear from Dr Karissa Barthelson, one of the latest Race Against Dementia Research Fellows from Flinders University – discussing her research, and specifically an introduction to Sanfilippo syndrome, a rare form of childhood dementia, and her research on this disease. Regular Dementia Researcher Bloggers Dr Anna Volkmer & Dr Kamar Ameen-Ali lead the interview, helping us to understand Karissa’s work and exploring the science. All types of neurodegenerative diseases share common molecular mechanisms responsible for disease etiology and progression. Karissa, is interested in understanding these shared mechanisms, as targeting the common problems could lead to new therapeutics to benefit more individuals who live with these diseases. To understand the shared molecular mechanisms, Karissa utilises zebra fish, as a model organism. Introducing mutations into zebrafish, equivalent to those which cause neurodegenerative diseases in humans (e.g., Alzheimer's disease, Sanfilippo syndrome childhood dementia), then analysing their brains with very high molecular detail. For more information about Sanfilippo syndrome visit: https://en.wikipedia.org/wiki/Sanfili... For more information on Race Against Dementia visit: https://www.raceagainstdementia.com You can find out more about our panellists, and their work on our website. There you will also find a full transcript: www.dementiaresearcher.nihr.ac.uk/podcast-researching-sanfilippo-syndrome -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. This podcast is brought to you in association with Alzheimer's Research UK and Alzheimer's Society, who we thank for their ongoing support. ~-~~-~~~-~~-~ Learn more about the new drugs coming to treat Alzheimer's Disea with this video podcast - "A Closer Look at Lecanemab, Donanemab and Amyloid"    • A Closer Look at Lecanemab, Donanemab and ...   ~-~~-~~~-~~-~